Neurocrine Biosciences Inc (NAS:NBIX)
$ 141.13 -0.87 (-0.61%) Market Cap: 14.20 Bil Enterprise Value: 13.55 Bil PE Ratio: 38.88 PB Ratio: 5.95 GF Score: 89/100

Neurocrine Biosciences Inc at Jefferies London Healthcare Conference (Virtual) Transcript

Nov 16, 2021 / 01:00PM GMT
Release Date Price: $88.27 (+0.56%)
Dingding Shi
Jefferies LLC, Research Division - Equity Analyst

Good morning, and good afternoon, depending on where you are. My name is Kelly Shi, one of the biotech analyst at the Jefferies. Thank you for attending our London Healthcare Conference. We are very pleased to have Neurocrine Management team for this session. From the [Neurocrine] are Mr. Kevin Gorman, Chief Executive Officer; Mr. Matthew Abernethy, Chief Financial Officer; and Mr. Kyle Gano, Chief BD and Strategy Officer. We will start out with the opening remarks by Kevin and followed by a fireside chat and the Q&A at the end. Kevin, welcome.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Thank you, Kelly, and it's good to be here in person for our first healthcare conference. I apologize for my voice. I've been getting over a cold. Yes, it's a cold that I have.

Before I start out, I would like to take this opportunity to direct people to our latest SEC filings because we will be making forward-looking statements here.

Neurocrine is a San Diego-based

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot